Tigris Starts Randomized Phase 2 Study of AFP-464

The primary endpoint of the study is to determine the percentage of patients that achieve a Clinical Benefit Response.

Tigris Pharmaceuticals, Inc., has announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex? (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients. The primary endpoint of the study is to determine the percentage of patients that achieve a Clinical Benefit Response.

Molecular profiling will be used to pre-screen patients for a biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown to predict sensitivity to AFP-464.

It is estimated that approximately 70 percent of breast cancers are ER-positive.

"The promise of personalized medicine is being realized